Seelos Therapeutics (SEEL) Competitors $0.35 -0.04 (-10.14%) (As of 11/19/2024 ET) Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends SEEL vs. PKBO, BLPH, BDRX, ELAB, NEXI, TCBP, SMFL, HSTO, TCON, and NAVBShould you be buying Seelos Therapeutics stock or one of its competitors? The main competitors of Seelos Therapeutics include Peak Bio (PKBO), Bellerophon Therapeutics (BLPH), Biodexa Pharmaceuticals (BDRX), Elevai Labs (ELAB), NexImmune (NEXI), TC Biopharm (TCBP), Smart for Life (SMFL), Histogen (HSTO), TRACON Pharmaceuticals (TCON), and Navidea Biopharmaceuticals (NAVB). These companies are all part of the "pharmaceutical products" industry. Seelos Therapeutics vs. Peak Bio Bellerophon Therapeutics Biodexa Pharmaceuticals Elevai Labs NexImmune TC Biopharm Smart for Life Histogen TRACON Pharmaceuticals Navidea Biopharmaceuticals Peak Bio (NASDAQ:PKBO) and Seelos Therapeutics (NASDAQ:SEEL) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, analyst recommendations, risk, institutional ownership, media sentiment, valuation, dividends, community ranking and profitability. Does the MarketBeat Community believe in PKBO or SEEL? Seelos Therapeutics received 70 more outperform votes than Peak Bio when rated by MarketBeat users. However, 100.00% of users gave Peak Bio an outperform vote while only 66.36% of users gave Seelos Therapeutics an outperform vote. CompanyUnderperformOutperformPeak BioOutperform Votes1100.00% Underperform VotesNo VotesSeelos TherapeuticsOutperform Votes7166.36% Underperform Votes3633.64% Which has more risk and volatility, PKBO or SEEL? Peak Bio has a beta of 1.75, suggesting that its share price is 75% more volatile than the S&P 500. Comparatively, Seelos Therapeutics has a beta of 1.94, suggesting that its share price is 94% more volatile than the S&P 500. Which has better valuation and earnings, PKBO or SEEL? Peak Bio has higher earnings, but lower revenue than Seelos Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioPeak Bio$370K1.41-$12.83M-$0.16-0.14Seelos Therapeutics$2.20M0.06-$37.88MN/AN/A Do insiders & institutionals believe in PKBO or SEEL? 23.4% of Seelos Therapeutics shares are held by institutional investors. 19.9% of Peak Bio shares are held by insiders. Comparatively, 1.1% of Seelos Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth. Is PKBO or SEEL more profitable? Seelos Therapeutics has a net margin of 203.13% compared to Peak Bio's net margin of 0.00%. Company Net Margins Return on Equity Return on Assets Peak BioN/A N/A -179.31% Seelos Therapeutics 203.13%N/A -431.47% Does the media refer more to PKBO or SEEL? In the previous week, Peak Bio had 2 more articles in the media than Seelos Therapeutics. MarketBeat recorded 2 mentions for Peak Bio and 0 mentions for Seelos Therapeutics. Peak Bio's average media sentiment score of 0.22 beat Seelos Therapeutics' score of 0.00 indicating that Peak Bio is being referred to more favorably in the media. Company Overall Sentiment Peak Bio Neutral Seelos Therapeutics Neutral SummaryPeak Bio beats Seelos Therapeutics on 7 of the 12 factors compared between the two stocks. Ad Crypto 101 Media“Sleeping Giant” Crypto Set to Explode…What if I told you there's a crypto that could make Bitcoin look like small change? We're looking at potential returns that could rewrite your financial future. Click here to discover our #1 crypto pick before it's too late Get Seelos Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for SEEL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SEEL vs. The Competition Export to ExcelMetricSeelos TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$131,000.00$6.42B$4.99B$8.72BDividend YieldN/A8.11%5.18%4.07%P/E RatioN/A10.06131.8117.48Price / Sales0.06318.981,206.0088.42Price / CashN/A22.1633.2732.46Price / Book0.005.454.654.64Net Income-$37.88M$152.96M$117.88M$224.75M7 Day Performance-49.37%-4.50%-2.58%-2.40%1 Month Performance-64.91%-8.85%-4.16%-0.32%1 Year Performance-99.93%28.65%29.52%24.05% Seelos Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SEELSeelos TherapeuticsN/A$0.35-10.1%N/A-99.9%$131,000.00$2.20M0.0020Gap DownPKBOPeak BioN/A$0.02-67.9%N/A-71.8%$520,000.00$370,000.00-0.143Gap DownHigh Trading VolumeBLPHBellerophon Therapeutics0.5195 of 5 stars$0.04flatN/A+13.0%$465,000.00N/A-0.0420BDRXBiodexa Pharmaceuticals2.5841 of 5 stars$3.85+7.2%$200.00+5,094.8%N/A$458,000.00$83,000.000.0021Gap UpELABElevai Labs0.3986 of 5 stars$0.02flatN/AN/A$445,000.00$1.71M-0.0718High Trading VolumeNEXINexImmuneN/A$0.24+14.3%N/A-91.6%$335,000.00N/A-0.016News CoverageTCBPTC Biopharm0.2924 of 5 stars$0.63+5.0%N/A-99.4%$333,000.00$4.76M0.0041SMFLSmart for LifeN/A$0.05flatN/A-99.6%$326,000.00$11.11M0.00110Gap DownHSTOHistogenN/A$0.03flatN/A-36.8%$115,000.00$19,000.00-0.017Gap DownTCONTRACON Pharmaceuticals1.2356 of 5 stars$0.03flat$60.00+199,900.0%-99.1%$102,000.00$12.05M0.0120Gap UpNAVBNavidea BiopharmaceuticalsN/A$0.00flatN/A-98.5%$100,000.00$70,000.00-0.0210 Related Companies and Tools Related Companies PKBO Competitors BLPH Competitors BDRX Competitors ELAB Competitors NEXI Competitors TCBP Competitors SMFL Competitors HSTO Competitors TCON Competitors NAVB Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:SEEL) was last updated on 11/20/2024 by MarketBeat.com Staff From Our PartnersTesla Execs are Freaking OutIt’s so revolutionary that tech giants like Microsoft, Amazon, and NVIDIA are all lining up to get their hands...Angel Publishing | Sponsored[625,000% Gain] – Are You Ready for the Next Altcoin Boom?All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you k...Crypto Swap Profits | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredDeFi Coin on Verge of Breakout!The blueprint for millionaires is here. Don't let this be the missed opportunity you regret for years. Crypto 101 Media | SponsoredTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersTrump quietly left open an "off the books" wealth-protection loophole hidden in the 6,871 pages of the IRS Tax...Colonial Metals | SponsoredBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThis company will win the AI race Rome wasn’t built in a day… But there is another lesser-known type of keystone, one that plays an equally c...Porter & Company | SponsoredThe smart-money is buying this US$1 lithium stockLithium is getting white-hot once again! And that means well-timed investors who position now in the best n...Resource Stock Digest | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Seelos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Seelos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
